HTG Signs Collaboration Agreement with Harvard Catalyst Laboratory
News Dec 02, 2008
HTG, Inc. has announced a collaboration agreement with researchers at Harvard Catalyst Laboratory for Innovative Translational Technologies (HC-LITT) at Harvard Medical School.
Under the terms of the agreement, HTG and HC-LITT will collaborate to generate a novel microRNA biogenesis assay that can measure expression of both pre-microRNA precursors, mature-microRNAs and regulated RNA using HTG's qNPA™ (quantitative Nuclease Protection Assay) technology.
Researchers at the HC-LITT are investigating the implications of differential microRNA expression in human diseases such as cancer. MicroRNAs are single-stranded functional RNA species encoded in the human genome that regulate protein expression of numerous gene products.
HC-LITT will utilize HTG’s technology to evaluate regulation of miRNA biogenesis by established oncogenic cell signaling pathways in order to develop novel diagnostic markers and therapeutic targets for the molecular characterization and treatment of cancer.
“We selected HTG’s technology due to the high precision and sensitivity of the product platform,” said Winston Patrick Kuo, Director, Harvard Catalyst Laboratory for Innovative Translational Technologies at Harvard Medical School. “I’m looking forward to utilizing HTG’s gene expression assay technology and imagers for HC-LITT’s research initiatives.”
HTG’s qNPA technology is used to carry out quantitative, multiplexed gene-based drug discovery programs, including target validation, HTS lead optimization, metabolism, toxicology and clinical development.
HTG’s platform is flexible and designed for high throughput automation; it allows scientists to test any sample, including fixed tissues, without RNA extraction or target amplification. The technology is ideal for detecting small yet important changes in gene expression levels which other gene expression platforms cannot reliably detect.
Largest Genetic Study of Osteoarthritis Advances ResearchNews
Osteoarthritis is a complex disease, and the genetic basis of the disease has proved difficult to pin down. A new study from the Sanger Institute provides much-needed hope.READ MORE
Exposure to Low Levels of BPA during Pregnancy Can Lead to Altered Brain DevelopmentNews
New research in mice provides an explanation for how exposure to the widely used chemical bisphenol A (BPA) during pregnancy, even at levels lower than the regulated “safe” human exposure level, can lead to altered brain development and behavior later in life.READ MORE
Moving Toward a Future Free of Drug-Induced Hearing LossNews
A new special publication orchestrated by five of the nation's leading hearing experts compiles the latest research into hearing loss caused by drugs and solvents - how it occurs, how to treat it, and how to prevent it.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Pharmacy and Clinical Research
Jul 16 - Jul 17, 2018
11th International Conference and Exhibition on Metabolomics & Systems Biology
May 17 - May 19, 2018
6th Annual Congress on Biology and Medicine of Molecules
Sep 17 - Sep 18, 2018